Lorlatinib……………………25mg

INDICATION:  

LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

The post LuciLorla-25mg first appeared on Gold Tree Pharmaceuticals.

Each film-coated LuciFine tablet contains: finerenone 10mg

INDICATION: 

LuciFine is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

DOSAGE AND USE:

· The recommended starting dosage is 10 mg or 20 mg orally once daily based on estimated glomerular filtration rate (eGFR) and serum potassium thresholds.

· Increase dosage after 4 weeks to the target dose of 20 mg once daily, based on eGFR and serum potassium thresholds.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children.

Do not administered LuciFine in Pregnancy and Lactation patient treatment.

The post LUCIFINE first appeared on Gold Tree Pharmaceuticals.

Each LuciMob capsule contains: 48.06mg Mobocertinib succinate equivalent to Mobocertinib 40mg

INDICATION: 

LuciMob is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

DOSAGE AND USE:

The recommended dosage of LuciMob is 160 mg orally once daily until disease progression or unacceptable toxicity.

Capsule should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciMob in Pregnancy and Lactation patient treatment.

The post LuciMob first appeared on Gold Tree Pharmaceuticals.

Each LuciVos tablet contains: Ivosidenib…………………… 250mg

INDICATION:  

LuciVos is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by

1. Newly Diagnosed Acute Myeloid Leukemia (AML)

· In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

2. Relapsed or refractory AML

· For the treatment of adult patients with relapsed or refractory AML.

3. Locally Advanced or Metastatic Cholangiocarcinoma

· For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.

DOSAGE AND USE:

1. Newly Diagnosed AML (Combination Regimen)

The recommended dosage of LuciVos is 500 mg taken orally once daily until disease progression or unacceptable toxicity. Start LuciVos administration on Cycle 1 Day 1 in combination with azacitidine 75 mg/m2 subcutaneously or intravenously once daily on Days 1-7 (or Days 1-5 and 8-9) of each 28-day cycle.

For patients without disease progression or unacceptable toxicity, continue LuciVos, in combination with azacitidine, for a minimum of 6 months to allow time for clinical response.

2. Newly Diagnosed AML and Relapsed or Refractory AML (Monotherapy Regimen)

The recommended dosage of LuciVos is 500 mg taken orally once daily until disease progression or unacceptable toxicity.

For patients without disease progression or unacceptable toxicity, continue LuciVos for a minimum of 6 months to allow time for clinical response.

3. Cholangiocarcinoma The recommended dosage of LuciVos is 500 mg taken orally once daily until disease progression or unacceptable toxicity.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciVos in Pregnancy and Lactation patient treatment.

The post LuciVos first appeared on Gold Tree Pharmaceuticals.

Avatrombopag maleate 23.6mg equivalent to avatrombopag 20mg

INDICATION: 

LuciAvat is a thrombopoietin receptor agonist indicated for the treatment of:

· Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

· Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

DOSAGE AND USE:

1. Chronic Liver Disease: Dose LuciAvat based upon platelet count prior to procedure, orally for 5 days beginning 10 to 13 days before procedure. For platelet count less than 40 × 10⁹/L, the dose is 60 mg (3 tablets) once daily; for platelet count 40 to less than 50 × 10⁹/L, the dose is 40 mg (2 tablets) once daily.

2. Chronic Immune Thrombocytopenia: Initiate LuciAvat at 20 mg (1 tablet) once daily. Adjust the dose or frequency of dosing to maintain platelet count greater than or equal to 50 × 10⁹ /L. Do not exceed 40 mg per day.

Tablets should be swallowed whole & not chewed or crushed and with food.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

The post LuciAvat first appeared on Gold Tree Pharmaceuticals.

Crizotinib 250mg

INDICATION:  

LuciCriz is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.

DOSAGE AND USE:

The recommended dosage is 250 mg orally twice daily.

Capsules should be swallowed whole & not chewed or crushed.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

The post LuciCriz first appeared on Gold Tree Pharmaceuticals.

Cabozantinib 20mg

INDICATION:  

LuciCaboz a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

DOSAGE AND USE:

Recommended Dose: 140 mg orally, once daily. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking LuciCaboz.

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

The post LuciCaboz first appeared on Gold Tree Pharmaceuticals.

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

INDICATION: 

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

LuciTram is indicated, in combination with dabrafenib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

DOSAGE AND USE:

The recommended dosage of LuciTram is 2 mg orally once daily. Take LuciTram at least 1 hour before or at least 2 hours after a meal.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 2°C to 8°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciTram in Pregnancy and Lactation patient treatment.

The post LuciTram first appeared on Gold Tree Pharmaceuticals.

Each film-coated LuciOsim tablet contains: Osimertinib……………………………80mg

INDICATIONS:

the treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test and the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

WARNINGS AND PRECAUTIONS:

1. Interstitial Lung Disease (ILD)/Pneumonitis: Permanently discontinue LuciOsim in patients diagnosed with ILD/Pneumonitis.

2. QTc interval Prolongation: Monitor electrocardiograms and electrolytes in patients who have a history or predisposition for QTc prolongation, or those who are taking medications that are known to prolong the QTc interval. Withhold then restart at a reduced does or permanently discontinue LuciOsim.

3. Cardiomyopathy: Conduct cardiac monitoring, including left ventricular ejection fraction(LVEF) assessment in patients with cardiac risk factors.

4. Keratitis: Promptly refer patients with signs and symptoms of keratitis to an ophthalmologist for evaluation.

5. Erythema Multiforme and Stevens-Johnson Syndrome: Withhold LuciOsim if erythema multiforme major (EMM) or Stevens-Johnson Syndrome (SJS) is suspected and permanently discontinue if confirmed.

6. Embryo-Fetal Toxicity: LuciOsim can cause fetal harm. Advise females of potential risk to the fetus and to use effective contraception during treatment with LuciOsim and for 6 weeks after final dose. Advise males to use effective contraception for 4 months, after the last does of LuciOsim.

ADVERSE REACTIONS:

Most common adverse reaction(≥ 20%) are diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

DOSAGE:

Recommended dosage: 80mg orally once daily, with or without food.

PRESENTATION:

Tablets: 80mg, Bottle of 30 Tablets,

STORAGE:

Store at 20°C to 25°C (77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

The post LuciOsim first appeared on Gold Tree Pharmaceuticals.

Each tablet contains: Enasidenib……… 50mg

INDICATION: 

LuciEna is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.

DOSAGE AND USE:

The recommended dosage of LuciEna is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciEna in Pregnancy and Lactation patient treatment.

The post LLUCIENA first appeared on Gold Tree Pharmaceuticals.